Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, announced that it has appointed Alex Rothwell as the Company’s new Chief Financial Officer, effective immediately.
Bruce Cousins, the Company’s outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities.
“Having previously served as Eupraxia’s CFO, and after that as our capital markets consultant, we are delighted to have Alex return and take over from Bruce. I believe his public markets and deal expertise, and his deep familiarity with Eupraxia and its shareholders, will make Alex a key contributor to our senior leadership team as Eupraxia advances its programs in EP-104GI and EP-104AR,” said James Helliwell, Chief Executive Officer of Eupraxia. “On behalf of our board of directors, I’d like to thank Bruce for his leadership and many important contributions to Eupraxia’s success including the Company’s recent Nasdaq listing, and his efforts strengthening our balance sheet, which gives us a solid foundation to build on.”
Health Technology Insights: Telix Completes Acquisition of Next-Generation Therapeutic Assets
Based in Victoria, B.C., Mr. Rothwell brings more than 25 years of experience as a business leader and as a senior executive in the Canadian capital markets and investment banking. He previously served as the CFO of Eupraxia from 2018-2021, and most recently has been a Senior Advisor to Fort Capital Partners, a Canadian boutique investment bank.
In 1995, he began his capital markets career in institutional equities and merger arbitrage, establishing himself over the next decade in various leadership roles at leading Canadian investment banks. He was appointed President and Executive Director of Macquarie Capital Markets Canada and ran its equities business for seven years before moving to British Columbia in late 2015.
Health Technology Insights: Court Square Capital Partners and WindRose Health Investors Announce Joint Investment in Soleo Health
Over the course of his career, he has advised public and private companies on their growth and acquisition strategies and associated funding requirements and has raised billions of dollars for them in structures ranging from early-stage investment rounds to large IPOs and follow-on offerings.
Mr. Rothwell holds a Bachelor of Chemical Engineering from McGill University (1991) and an MBA from the Ivey School of Business (1995).
“I believe that Eupraxia is in an excellent position to create significant value for shareholders, and I’m very focused on helping drive that process. There is significant unrealized – and unrecognized – potential in the assets, and I have confidence that we can deliver on that potential for patients and shareholders,” said Alex Rothwell, new Chief Financial Officer of Eupraxia. “EP-104GI has an opportunity to be the leading treatment for Eosinophilic Esophagitis, and associated conditions such as strictures. Additionally, we anticipate that EP-104IAR, for the treatment of pain due to osteoarthritis of the knee, can become a key therapy to treat this large patient population, and that its market can be materially expanded by use in other joint areas.”
Health Technology Insights: The Cigna Group Launches Actions To Drive Positive Change for Customers and Patients
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source: PR Newswire
